Pharma & Human Health
AOB Pharma receives EMA positive decision on the Pediatric Investigation Plan for development of B244
AOB Pharma, Inc. (“AOBiome”), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions with their lead asset B244 for the treatment of mild to moderate atopic dermatitis (AD) and pruritus, received a positive decision […]